226 related articles for article (PubMed ID: 24191914)
1. Bepotastine besilate for the treatment of pruritus.
Bielory L; Duttachoudhury S; McMunn A
Expert Opin Pharmacother; 2013 Dec; 14(18):2553-69. PubMed ID: 24191914
[TBL] [Abstract][Full Text] [Related]
2. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
3. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
4. Oral bepotastine: in allergic disorders.
Lyseng-Williamson KA
Drugs; 2010 Aug; 70(12):1579-91. PubMed ID: 20687621
[TBL] [Abstract][Full Text] [Related]
5. Bepotastine besilate for the treatment of perennial allergic rhinitis.
Carrillo-Martin I; Gonzalez-Estrada A; Dimov V
Expert Opin Pharmacother; 2018 Oct; 19(15):1727-1730. PubMed ID: 30208284
[TBL] [Abstract][Full Text] [Related]
6. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
7. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate.
Williams JI; Gow JA; Klier SM; McCue SL; Salapatek AM; McNamara TR
Curr Med Res Opin; 2010 Oct; 26(10):2329-38. PubMed ID: 20735291
[TBL] [Abstract][Full Text] [Related]
8. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
Torkildsen GL; Williams JI; Gow JA; Gomes PJ; Abelson MB; McNamara TR;
Ann Allergy Asthma Immunol; 2010 Jul; 105(1):57-64. PubMed ID: 20642205
[TBL] [Abstract][Full Text] [Related]
9. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Macejko TT; Bergmann MT; Williams JI; Gow JA; Gomes PJ; McNamara TR; Abelson MB;
Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
[TBL] [Abstract][Full Text] [Related]
10. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
Meier EJ; Torkildsen GL; Gow JA; McNamara TR; Gomes PJ; Williams JI;
Allergy Asthma Proc; 2012; 33(3):265-74. PubMed ID: 22991696
[TBL] [Abstract][Full Text] [Related]
11. Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis.
Okubo K; Ichimura M; Koyama T; Susuta Y; Izaki H
Expert Opin Pharmacother; 2015; 16(16):2395-408. PubMed ID: 26364765
[TBL] [Abstract][Full Text] [Related]
12. Bepotastine (bepreve)--an ophthalmic H1-antihistamine.
Med Lett Drugs Ther; 2010 Feb; 52(1331):11-2. PubMed ID: 20216525
[No Abstract] [Full Text] [Related]
13. H1-antihistamines in the elderly.
Kaliner MA
Clin Allergy Immunol; 2002; 17():465-81. PubMed ID: 12113227
[TBL] [Abstract][Full Text] [Related]
14. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice.
Andoh T; Kuraishi Y
Eur J Pharmacol; 2006 Oct; 547(1-3):59-64. PubMed ID: 16914135
[TBL] [Abstract][Full Text] [Related]
15. Clinical profile of astemizole. A survey of 50 double-blind trials.
Vanden Bussche G; Emanuel MB; Rombaut N
Ann Allergy; 1987 Mar; 58(3):184-8. PubMed ID: 2881507
[TBL] [Abstract][Full Text] [Related]
16. Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis.
Bartra J; Mullol J; Montoro J; Jáuregui I; del Cuvillos A; Dávila I; Ferrer M; Sastre J; Valero A
J Investig Allergol Clin Immunol; 2011; 21 Suppl 3():24-33. PubMed ID: 22185047
[TBL] [Abstract][Full Text] [Related]
17. Ebastine in allergic rhinitis and chronic idiopathic urticaria.
Sastre J
Allergy; 2008 Dec; 63 Suppl 89():1-20. PubMed ID: 19032340
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of bilastine: 2nd generation H1-antihistamines.
Scaglione F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
[TBL] [Abstract][Full Text] [Related]
20. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.
Jáuregui I; García-Lirio E; Soriano AM; Gamboa PM; Antépara I
Expert Rev Clin Immunol; 2012 Jan; 8(1):33-41. PubMed ID: 22149338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
